METHODS OF USING AND COMPOSITIONS CONTAINING DULAGLUTIDE

To provide methods of using new doses of dulaglutide for treating type 2 diabetes.SOLUTION: The present invention provides a method of improving glycemic control in a subject having type 2 diabetes (T2D) and in need of additional glycemic control, comprising: a) identifying a subject having T2D and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: ANDREW GORDON WERNER, DAVID BRADLEY WOODWARD, LAI SAN THAM, DAVID ANDREW COX, ZVONKO MILICEVIC
Format: Patent
Sprache:eng ; jpn
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator ANDREW GORDON WERNER
DAVID BRADLEY WOODWARD
LAI SAN THAM
DAVID ANDREW COX
ZVONKO MILICEVIC
description To provide methods of using new doses of dulaglutide for treating type 2 diabetes.SOLUTION: The present invention provides a method of improving glycemic control in a subject having type 2 diabetes (T2D) and in need of additional glycemic control, comprising: a) identifying a subject having T2D and in need of further glycemic control; b) administering to the subject a first dose of dulaglutide once weekly for a minimum of four weeks; and c) increasing the dose to a second dose administered once weekly, wherein the first dose is selected from the group consisting of 1.5 and 3.0 mg, and the second dose is selected from the group consisting of 3.0 and 4.5 mg.SELECTED DRAWING: None 【課題】2型糖尿病を治療するための、デュラグルチドの新用量を使用する方法を提供する。【解決手段】2型糖尿病(T2D)を有しかつ追加の血糖コントロールを必要とする対象において血糖コントロールを改善する方法であって、a)T2Dを有しかつさらなる血糖コントロールを必要とする対象を同定すること、b)前記対象に週に1回の第1の用量のデュラグルチドを最低4週間投与すること、及びc)用量を週に1回投与される第2の用量に増加させること、を含み、前記第1の用量が1.5及び3.0mgからなる群から選択され、かつ、前記第2の用量が3.0及び4.5mgからなる群から選択される、方法である。【選択図】なし
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JP2024056908A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JP2024056908A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JP2024056908A3</originalsourceid><addsrcrecordid>eNrjZLDwdQ3x8HcJVvB3UwgN9vRzV3D0c1Fw9vcN8A_2DPH09wsGcvxCHD39QHIuoT6O7j6hIZ4urjwMrGmJOcWpvFCam0HJzTXE2UM3tSA_PrW4IDE5NS-1JN4rwMjAyMTA1MzSwMLRmChFAMbNKSI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>METHODS OF USING AND COMPOSITIONS CONTAINING DULAGLUTIDE</title><source>esp@cenet</source><creator>ANDREW GORDON WERNER ; DAVID BRADLEY WOODWARD ; LAI SAN THAM ; DAVID ANDREW COX ; ZVONKO MILICEVIC</creator><creatorcontrib>ANDREW GORDON WERNER ; DAVID BRADLEY WOODWARD ; LAI SAN THAM ; DAVID ANDREW COX ; ZVONKO MILICEVIC</creatorcontrib><description>To provide methods of using new doses of dulaglutide for treating type 2 diabetes.SOLUTION: The present invention provides a method of improving glycemic control in a subject having type 2 diabetes (T2D) and in need of additional glycemic control, comprising: a) identifying a subject having T2D and in need of further glycemic control; b) administering to the subject a first dose of dulaglutide once weekly for a minimum of four weeks; and c) increasing the dose to a second dose administered once weekly, wherein the first dose is selected from the group consisting of 1.5 and 3.0 mg, and the second dose is selected from the group consisting of 3.0 and 4.5 mg.SELECTED DRAWING: None 【課題】2型糖尿病を治療するための、デュラグルチドの新用量を使用する方法を提供する。【解決手段】2型糖尿病(T2D)を有しかつ追加の血糖コントロールを必要とする対象において血糖コントロールを改善する方法であって、a)T2Dを有しかつさらなる血糖コントロールを必要とする対象を同定すること、b)前記対象に週に1回の第1の用量のデュラグルチドを最低4週間投与すること、及びc)用量を週に1回投与される第2の用量に増加させること、を含み、前記第1の用量が1.5及び3.0mgからなる群から選択され、かつ、前記第2の用量が3.0及び4.5mgからなる群から選択される、方法である。【選択図】なし</description><language>eng ; jpn</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240423&amp;DB=EPODOC&amp;CC=JP&amp;NR=2024056908A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240423&amp;DB=EPODOC&amp;CC=JP&amp;NR=2024056908A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ANDREW GORDON WERNER</creatorcontrib><creatorcontrib>DAVID BRADLEY WOODWARD</creatorcontrib><creatorcontrib>LAI SAN THAM</creatorcontrib><creatorcontrib>DAVID ANDREW COX</creatorcontrib><creatorcontrib>ZVONKO MILICEVIC</creatorcontrib><title>METHODS OF USING AND COMPOSITIONS CONTAINING DULAGLUTIDE</title><description>To provide methods of using new doses of dulaglutide for treating type 2 diabetes.SOLUTION: The present invention provides a method of improving glycemic control in a subject having type 2 diabetes (T2D) and in need of additional glycemic control, comprising: a) identifying a subject having T2D and in need of further glycemic control; b) administering to the subject a first dose of dulaglutide once weekly for a minimum of four weeks; and c) increasing the dose to a second dose administered once weekly, wherein the first dose is selected from the group consisting of 1.5 and 3.0 mg, and the second dose is selected from the group consisting of 3.0 and 4.5 mg.SELECTED DRAWING: None 【課題】2型糖尿病を治療するための、デュラグルチドの新用量を使用する方法を提供する。【解決手段】2型糖尿病(T2D)を有しかつ追加の血糖コントロールを必要とする対象において血糖コントロールを改善する方法であって、a)T2Dを有しかつさらなる血糖コントロールを必要とする対象を同定すること、b)前記対象に週に1回の第1の用量のデュラグルチドを最低4週間投与すること、及びc)用量を週に1回投与される第2の用量に増加させること、を含み、前記第1の用量が1.5及び3.0mgからなる群から選択され、かつ、前記第2の用量が3.0及び4.5mgからなる群から選択される、方法である。【選択図】なし</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLDwdQ3x8HcJVvB3UwgN9vRzV3D0c1Fw9vcN8A_2DPH09wsGcvxCHD39QHIuoT6O7j6hIZ4urjwMrGmJOcWpvFCam0HJzTXE2UM3tSA_PrW4IDE5NS-1JN4rwMjAyMTA1MzSwMLRmChFAMbNKSI</recordid><startdate>20240423</startdate><enddate>20240423</enddate><creator>ANDREW GORDON WERNER</creator><creator>DAVID BRADLEY WOODWARD</creator><creator>LAI SAN THAM</creator><creator>DAVID ANDREW COX</creator><creator>ZVONKO MILICEVIC</creator><scope>EVB</scope></search><sort><creationdate>20240423</creationdate><title>METHODS OF USING AND COMPOSITIONS CONTAINING DULAGLUTIDE</title><author>ANDREW GORDON WERNER ; DAVID BRADLEY WOODWARD ; LAI SAN THAM ; DAVID ANDREW COX ; ZVONKO MILICEVIC</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JP2024056908A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; jpn</language><creationdate>2024</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>ANDREW GORDON WERNER</creatorcontrib><creatorcontrib>DAVID BRADLEY WOODWARD</creatorcontrib><creatorcontrib>LAI SAN THAM</creatorcontrib><creatorcontrib>DAVID ANDREW COX</creatorcontrib><creatorcontrib>ZVONKO MILICEVIC</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ANDREW GORDON WERNER</au><au>DAVID BRADLEY WOODWARD</au><au>LAI SAN THAM</au><au>DAVID ANDREW COX</au><au>ZVONKO MILICEVIC</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>METHODS OF USING AND COMPOSITIONS CONTAINING DULAGLUTIDE</title><date>2024-04-23</date><risdate>2024</risdate><abstract>To provide methods of using new doses of dulaglutide for treating type 2 diabetes.SOLUTION: The present invention provides a method of improving glycemic control in a subject having type 2 diabetes (T2D) and in need of additional glycemic control, comprising: a) identifying a subject having T2D and in need of further glycemic control; b) administering to the subject a first dose of dulaglutide once weekly for a minimum of four weeks; and c) increasing the dose to a second dose administered once weekly, wherein the first dose is selected from the group consisting of 1.5 and 3.0 mg, and the second dose is selected from the group consisting of 3.0 and 4.5 mg.SELECTED DRAWING: None 【課題】2型糖尿病を治療するための、デュラグルチドの新用量を使用する方法を提供する。【解決手段】2型糖尿病(T2D)を有しかつ追加の血糖コントロールを必要とする対象において血糖コントロールを改善する方法であって、a)T2Dを有しかつさらなる血糖コントロールを必要とする対象を同定すること、b)前記対象に週に1回の第1の用量のデュラグルチドを最低4週間投与すること、及びc)用量を週に1回投与される第2の用量に増加させること、を含み、前記第1の用量が1.5及び3.0mgからなる群から選択され、かつ、前記第2の用量が3.0及び4.5mgからなる群から選択される、方法である。【選択図】なし</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; jpn
recordid cdi_epo_espacenet_JP2024056908A
source esp@cenet
subjects BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
title METHODS OF USING AND COMPOSITIONS CONTAINING DULAGLUTIDE
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T18%3A57%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ANDREW%20GORDON%20WERNER&rft.date=2024-04-23&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJP2024056908A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true